Drug intelligence / Profile preview

Ejiao Qianggu Oral Liquid

Development stage: Unknown
Lead developer: Xinjiang Huasidan Pharmaceutical Research
Administration: Oral

Overview

Ejiao Qianggu Oral Liquid is a traditional Chinese medicine (TCM) developed by Xinjiang Huasidan Pharmaceutical Research. Formulated as an oral liquid, it is primarily indicated for bone strengthening and the treatment or prevention of osteoporosis. The preparation likely utilizes Ejiao (Colla Corii Asini) as a key component, a substance traditionally used in Chinese medicine to tonify blood and essence, which is believed to support bone health. The drug is currently categorized as an approved product, specifically noted for being in a stage of secondary development or re-development by the sponsor to enhance its clinical profile or regulatory positioning.

Brand names: Ejiao Qianggu Oral Liquid
Other names: 阿胶强骨口服液Ejiao Qianggu KoufuyeEjiao Qianggu

Beyond the preview

Go deeper on Ejiao Qianggu Oral Liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ejiao Qianggu Oral Liquid.

Explore the full profile